Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
A phase II trial of PALA in malignant lymphoma was carried out by the Eastern Cooperative Oncology Group. The occurrence of hematologic toxicity in 17 of 35 patients in the study was noteworthy and was possibly related to prior therapy and/or marrow involvement. The finding of thromboembolic phenomena in four of five autopsied patients was also noteworthy. No antitumor activity was recorded. This experience discourages further trials of PALA in patients with malignant lymphoma.
D000328:Adult; D000368:Aged; D001224:Aspartic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004064:Digestive System / Q000187:drug effects; D003875:Drug Eruptions; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced
D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid